Metal-Bronsted Acid Cooperative Catalysis for Asymmetric Direct Reductive Amination

Lead Research Organisation: University of Liverpool
Department Name: Chemistry

Abstract

Chiral amines are ubiquitous in nature and are the most common functionalities in drug molecules, fine chemicals and new materials. They can be prepared by a number of methods; but the simplest, most efficient and eco-benign preparation is asymmetric direct reductive amination (ADRA) of ketones with hydrogen, which produces chiral amines in one pot. However, this reaction has not found applications in commercial synthesis, because literally no good catalysts are yet available. This proposal attempts to address this Holy Gail problem facing chemical synthesis and asymmetric catalysis by exploiting a novel strategy, Metal-Bronsted Acid Cooperative Catalysis (MBCC). Unlike traditional chemistry developed for ADRA, our approach incorporates three new elements: ionic catalysis, electrophilic activation, and counter anion-directed chiral induction. Under MBCC, an amine condenses with a ketone, forming an imine; this is catalyzed by the Bronsted acid. More importantly, the Bronsted acid then protonates, and thereby activates, the resulting imine by converting it into a highly electrophilic iminium ion. Subsequent hydride transfer, now with a lower barrier, from the metal centre to the iminium carbon atom reduces the C=N double bond. Last not the least, the hydride transfer to which enantiotopic face of the C=N double bond is aided by the conjugate base of the acid through ion-pairing. Clearly, the acid will play a key role in the operation of MBCC, which we believe stands for the most promising approach thus far for developing ADAR. Whilst the concept is designed for ADRA, its potential utility is expected to be much wider. The proposal builds on our recent highly successful studies of asymmetric hydrogenation of imines, key intermediates in ADRA, where unprecedented enantioselectivities have been recorded for a wide range of imines. A key discovery is the use of both hydrogenating metal catalyst and Bronsted acids. Our preliminary results indicate that MBCC drives the reaction and dictates the face selection, pointing to the potential of tackling ADRA via MBCC. However, we have not been able to carry out any mechanistic investigations yet. In order to most efficiently develop catalysts for ADAR by rational design, this project will be built on our preliminary results informed by mechanistic studies. The project will be divided into two synergistic parts, experimental exploration of MBCC for ADRA, and mechanistic and theoretical investigations. We believe experiments alone cannot answer key mechanistic questions, while mechanistic studies can only aid, but not replace, the discovery process
 
Description The combination of a chiral phosphoric acid with a chiral or an achiral iridium complex affords a catalyst that allows for highly enantioselective hydrogenation of imines and reductive amination. Mechanistic studies suggest that the hydrogenation proceeds through a ternary transition state at the hydride-transfer step, in which the organocatalyst interacts with both the hydride donor and acceptor, effecting highly effective chiral relay.
Exploitation Route The concept developed in the research has been and is being exploited by a number of researchers elsewhere, as is partially seen in the citation of our original publication (ca 250 citations, J. Am. Chem. Soc. 2009, 131, 6967) and the more recent mechanistic study (ca 50 citations, Angew. Chem. Int. Ed. 2013, 52, 1668).
A spin out company, Liverpool ChiroChem, was established partially as a result of this research.
The project contributed to the funding of a three-year Innovate UK KTP project (2019-2022) on asymmetric reduction of N-heterocycles. The knowledge gained will help develop new chiral catalysts for the KTP project.
Sectors Chemicals,Education,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology

 
Description Both Pfizer and AstraZeneca have provided PhD studentships directly or partially as a result of this research. A spin out company, Liverpool ChiroChem, was established partially as a result of this research. The project contributed to the funding of a three-year Innovate UK KTP project (2019-2022) on asymmetric reduction of N-heterocycles. The knowledge gained will help develop new chiral catalysts for the KTP project.
Sector Chemicals,Education,Manufacturing, including Industrial Biotechology,Pharmaceuticals and Medical Biotechnology
Impact Types Economic

 
Description KNOWLEDGE TRANSFER PARTNERSHIP between The University of Liverpool and Liverpool ChiroChem Limited
Amount £192,866 (GBP)
Funding ID KTP11214 
Organisation Innovate UK 
Sector Public
Country United Kingdom
Start 01/2019 
End 01/2022
 
Description Collaboration with Adisseo (France) on transfer hydrogenation 
Organisation Adisseo
Country France 
Sector Private 
PI Contribution Developed conditions for transfer hydrogenation of an Adisseo feedstock.
Collaborator Contribution Grant to fund a reseacher.
Impact Knowledge transfer to the company.
Start Year 2012
 
Description Collaboration with AstraZeneca on asymmetric hydrogantion 
Organisation AstraZeneca
Country United Kingdom 
Sector Private 
PI Contribution The university provided a PhD studentship.
Collaborator Contribution AZ provided a case award to top-up the studentship.
Impact The reseach is ongoing.
Start Year 2015
 
Description Collaboration with Pfizer on asymmetric transfer hydrogenation 
Organisation Pfizer Ltd
Country United Kingdom 
Sector Private 
PI Contribution Developed new catalysts for the reduction of N-heterocycles and a new reaction for accessing chiral piperidines.
Collaborator Contribution A PhD studentship.
Impact A PhD degree was awarded. Peer-reviewed publications: 1. Y. Wei, J. Wu, D. Xue, C. Wang, Z. Liu, Z. Zhang, G. Chen, J. Xiao, Synlett 2014, 25, 1295-1298. 2. J. Wu, W. Tang, A. Pettman, J. Xiao, Adv. Synth. Catal. 2013, 355, 35-40. 3. J. Wu, D. Talwar, S. Johnston, M. Yan, J. Xiao, Angew. Chem.-Int. Edit. 2013, 52, 6983-6987. 4. J. Wu, J. H. Barnard, Y. Zhang, D. Talwar, C. M. Robertson, J. Xiao, Chem. Commun. 2013, 49, 7052- 7054. 5. J. Wu, C. Wang, W. Tang, A. Pettman, J. Xiao, Chem.-Eur. J. 2012, 18, 9525-9529.
Start Year 2009
 
Title CATALYST COMPOUNDS 
Description The present invention relates to an iridium-based catalyst compound for hydrogenating reducible moieties, especially imines and iminiums, the catalyst compounds being defined by the formula: (Formula (I)) where ring B is a conjugated ring system with one or more substituents. The catalysts of the invention are particularly effective in reductive amination procedures which involve the in situ generation of the imine or iminium under reductive hydrogenative conditions. 
IP Reference WO2013153408 
Protection Patent granted
Year Protection Granted 2013
Licensed No
Impact The TSB-EPSRC project EP/K504166 is partly based on this invention, which involves two universities and six companies.
 
Title CATALYST COMPOUNDS 
Description The present invention relates to an iridium-based catalyst compound for hydrogenating reducible moieties, especially imines and iminiums, the catalyst compounds being defined by the formulas: where ring B is either itself polycyclic, or ring B together with R is polycyclic. The catalysts of the invention are particularly effective in reductive amination procedures 10 which involve the in situ generation of the imine or iminium under reductive hydrogenative conditions. 
IP Reference WO2013153407 
Protection Patent granted
Year Protection Granted 2013
Licensed No
Impact The TSB-EPSRC project EP/K504166 is partly based on this invention, which involves two universities and six companies.
 
Company Name Liverpool ChiroChem 
Description The company supplies specialist building blocks and chiral small molecules for pharmaceutical and biotech research/development and draws upon state-of-the-art synthetic methods in asymmetric catalysis developed at the University of Liverpool in collaboration with Pfizer. 
Year Established 2014 
Impact The company has recently won top prize in the 2015 Merseyside Innovation awards (http://www.merseysideinnovationawards.co.uk/news/liverpool-chirochem-take-the-2015-grand-prize/) and the Bionow Start Up of the Year Award 2015 (http://www.bionow.co.uk/news/the14thbionowannualawardssuccessfullyshowcas.aspx).
Website http://www.liverpoolchirochem.com/